Analytical Data
-
Gene name
Fbxo32
- Application
-
Alternative Names
Atrogin-1 (Muscle atrophy F-box protein) (MAFbx)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9CPU7
-
Expression Region
1-355aa
-
Molecular Weight
48.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FBXO32, also known as MuRF1 (Muscle RING Finger 1), is a member of the F-box protein family and plays a critical role in the ubiquitin-proteasome system, primarily involved in protein degradation. It is known to be a key regulator of muscle protein homeostasis, particularly during conditions such as muscle wasting or atrophy associated with diseases like cancer, diabetes, and aging. As a muscle-specific E3 ligase, FBXO32 targets various substrates, including key muscle regulatory proteins, for ubiquitin-mediated degradation, thereby influencing muscle mass and function. Given the increasing prevalence of muscle-related disorders, understanding the molecular mechanisms by which FBXO32 operates is crucial for developing therapeutic strategies. Recent studies have focused on the structural and functional characterization of FBXO32 recombinant proteins to elucidate its role in muscle atrophy and to explore potential interventions. These investigations aim to provide insights into how modulation of FBXO32 activity could mitigate muscle wasting and enhance muscle regeneration, with implications for treating conditions characterized by muscle loss. Researchers are also exploring the potential for FBXO32 as a biomarker for muscle health and its relevance in systemic diseases, reinforcing its significance in both basic and clinical research. Overall, the study of FBXO32 recombinant proteins bridges the gap between molecular biology and therapeutic application, highlighting its potential as a target for innovative treatments aimed at preserving muscle function and improving the quality of life for individuals suffering from muscle degenerative diseases.
